Cosmecca Korea Co., Ltd. Overview
Cosmecca Korea is the third-largest pure-play cosmetics ODM/OEM in Korea, behind Cosmax and Kolmar Korea. It brands its model as "OGM" (Original Global-standard Manufacturing). It formulates, develops, and manufactures skincare, functional/OTC, and colour cosmetics for third-party brands. It does not sell under its own consumer brands. Production runs through three entities:
-
The Korean parent, with plants in Eumseong and Cheongju and a new Ochang site under construction.
-
Majority-owned Englewood Lab, with plants in Totowa (New Jersey) and Incheon.
-
A small China subsidiary in Pinghu.
The investment case rests on the global boom in Korean indie and "K-derma" brands, whose exports flow through Korean ODMs. From FY2023 to FY2025, consolidated revenue rose from KRW 470.7 bn to KRW 640.9 bn and operating margin from 10.4% to 13.0%. 1H 2026 revenue grew 46.8%. The company has a medium-term revenue target of KRW 1 trillion and a ~KRW 200 bn capacity build-out at Ochang. Its US manufacturing base gives it a hedge against tariffs.
What the company does
Cosmecca Korea is a business-to-business cosmetics manufacturer. Its services cover:
-
formulation research and development,
-
product proposal and concept development (ODM),
-
contract manufacturing to customer specification (OEM),
-
quality assurance and regulatory support,
-
packaging procurement under "turnkey" contracts.
It serves brand owners: Korean indie brands, global prestige and mass beauty houses, and US indie and OTC brands.
S&P's company description, carried on StockHub, lists its products as:
-
skincare (lotions/toners, creams, essences, cleansers, mask sheets, scalp, body and bath products),
-
functional products (whitening, anti-wrinkle, UV protection, acne care),
-
colour cosmetics (BB/CC creams, foundation, lipstick, mascara).
Company self-description
The company now calls itself a "global cosmetics OGM (Original Global-standard Manufacturing) specialist." Management uses the term to stress:
-
production to international regulatory standards (Korea MFDS, US FDA OTC monograph, Health Canada, Australia TGA, halal),
-
a Korea–US two-hub structure,
-
proprietary formulation development.
The company credits its growth to the following (Cosmorning and CosinKorea, 2025–2026):
-
order wins from Korean and global indie brands,
-
new-format development (it claims it launched the world's first triple-function BB cream),
-
tailored proposals and fast response,
-
automation, including the "Cosmecca Production System (CPS)".
Independent characterisation
Economically, Cosmecca is a capacity-constrained, working-capital-intensive contract manufacturer whose volumes track its clients' sell-through. Key features:
Revenue model: almost entirely product revenue (per-unit manufacturing). Small service income exists (Englewood Lab reports ~3% "services," Q2 2026). There is no subscription or licensing revenue.
Turnkey vs. non-turnkey mix: this materially changes reported revenue but not necessarily margin. Under turnkey contracts Cosmecca buys the containers and passes their cost through in the price. Under non-turnkey ("용기 사급") contracts the client supplies packaging. A large Englewood Lab Korea client switched to non-turnkey in 2024, which depressed reported revenue (Yuanta, Jan 2025; Hana, Jul 2025).
Value-chain position: midstream. Upstream are raw-material and packaging suppliers; supply disruptions hit 2Q26 China results and the 3Q26 Korean results (KB, Oct 2026). Downstream are brand owners and, beyond them, retailers and marketplaces such as Amazon, TikTok Shop, Olive Young, Ulta and Sephora.
Customer types: - Korean indie/derma brands that export globally (the main growth driver since 2023).
-
Global multinationals (Estée Lauder was cited as a key US/EU client as early as FY2016; Hankyung, Feb 2017).
-
US indie and OTC sunscreen brands (Englewood Lab: >93% of revenue from US customers at end-2024; Dealsite, Aug 2025).
-
Chinese local and global brands (China subsidiary).
End-markets: prestige and masstige skincare, dermocosmetics, sun care/OTC, base and colour make-up (cushions, BB), masks (hydrogel), and expanding into hair and body care.
Customer concentration
The company does not name its clients. Broker commentary tracks them by letter:
-
At 4Q25, client "D" grew 35% QoQ and became the largest customer (KB, Feb 2026).
-
In 2Q26, client "A" entered the top ten, and customers ranked 5th–10th grew from ~1% to 2–3% of revenue each (Hana, Aug 2026).
-
At Englewood Lab Korea, orders from customer "G" weakened in 2Q26, cutting that unit's profit 13% YoY (Hana, Aug 2026).
These data show concentration is falling but still material.
Strategy
Stated strategic themes (paraphrased from company statements)
-
KRW 1 trillion revenue. The chairman set a medium-to-long-term goal of KRW 1 trn consolidated revenue in his 2025 New Year address. The company describes it as medium-term (Dealsite, Jul 2026). Hana's FY2027 estimate is KRW 1,024 bn.
-
"Global top-tier OGM." Become a top-tier global ODM through R&D investment, formulation diversification, and new orders from K-beauty and global indie brands (Chairman Cho, Nov 2025).
-
Korea–US dual production hub. Build "Made in USA" capacity and integrate Korea–US technology collaboration and product development. Unify ERP across the two entities to improve cost structure and link production and sales networks (company, Mar 2026).
-
Category expansion. Move from a skincare core into hydrogel masks, sun care, and premium hair and body (Ochang), and into OTC sunscreen (Englewood).
-
Customer diversification. Reduce dependence on top clients by deepening SKUs with existing clients and adding new indie brands.
-
Governance and capital-market upgrade. Build an audit committee, chair separation, and compliance programme, with a possible renewed KOSPI transfer. Management said no decision has been made.
-
2026 management keyword. A four-character motto, "비천도해" (飛天渡海; roughly "fly through the sky and cross the sea"), announced at the 2 January 2026 kickoff.
Initiatives in the last 24 months
| Initiative | Date | Scope / target | Status |
|---|---|---|---|
| Englewood Lab tender offer I | Feb 2025 | 39%→50%; ~KRW 21.9 bn | Completed |
| Englewood Lab tender offer II | Mar 2026 | 50%→66.7%; ~KRW 43.1 bn | Completed (25 Mar 2026) |
| Cheongju hydrogel-mask plant | Apr 2025 | >1m sheets/month initially | Operating |
| Englewood RTG OTC sunscreen platform | 1Q–2Q 2025 | FDA-compliant ready-to-go sunscreens | Launched; driving US growth |
| Englewood automation (Totowa, Incheon) | 2024–2025 | Productivity and margin | Effects visible (EWLK OPM 34% in 4Q25) |
| Sales reorganisation | Early 2025 | Domestic and global marketing merged into Global Sales Division | Done |
| China turnaround | 2025–2026 | New GM; halal; Shanghai R&D; target breakeven in 2026 (Yuanta, Feb 2026) | Still loss-making in 2Q26 |
| Pangyo Central Research Institute | 4Q 2025 | New R&D hub | Opened |
| KOSPI transfer attempt | May–Sep 2025 | Transfer listing | Failed KRX preliminary review |
| Governance overhaul | Mar 2026 | Audit committee, chair separation, 6 committees, e-voting | Done |
| Ochang plant acquisition | Jun 2026 | KRW 64 bn land and buildings | Agreed; Hansol says closing within 2026 |
| Ochang facility build-out | Sep 2026 | KRW 136 bn; first phase 2027; staged to 2030 | Announced |
| SP Beauty Global merger | Dec 2026 (planned) | Simplify US packaging ownership | Pending |
| Government "AI application product rapid commercialisation support programme" | 2026 (exact date not confirmed) | Selected participant | Reported (Asia Economy headline, Jul 2026) |
| ESG/packaging | Undated | MOU with Green Bio on biodegradable containers | Reported (Sellernow) |
Guidance
| Guidance item | Original (Feb 2026) | Revised (May 2026) | Revised (Aug 2026) |
|---|---|---|---|
| FY2026 consolidated revenue growth (%) | 15 | 20 | 30 |
| FY2026 operating margin (%) | 13.0 | 13.5 | Not captured in sources reviewed |
A 30% increase implies FY2026 revenue of ≈KRW 833 bn.
No formal medium-term margin or ROE targets were identified beyond the KRW 1 trn revenue ambition.
Products & Services
Cosmecca discloses no SKU-level pricing. Pricing is contract-based per unit, and turnkey contracts include packaging pass-through.
Korea (parent)
| Product line / capability | Description and capabilities | Target customer | Status / year | Flagship / evidence |
|---|---|---|---|---|
| Basic skincare (기초) | Toners, lotions, creams, essences/serums, ampoules; the core of the Korean book and the main margin driver | Korean indie and derma brands; global brands | Core since founding | Hana (Aug 2026): high-margin skincare focus drives Korean OPM to 13.7% in 2Q26 |
| K-derma / dermocosmetics | Skin-science formulations (barrier, calming, actives) | K-derma brands going global | Growth category 2025–26 | Company (CosinKorea, Aug 2026) cites rising global demand for K-derma; Kyobo highlights it |
| Cleansers | Cleansing oils, foams, balms | Indie brands | Ongoing | Company says its in-house-developed cleansing oil was an Amazon bestseller (Kukinews, Nov 2025) |
| Peel / exfoliating shots | Concentrated exfoliating serum format ("필샷", peel shot) | Indie brands | 2025 hit | Company says it reached TikTok best-seller status (Kukinews, Nov 2025) |
| Base make-up (BB/CC, cushion, foundation) | Multi-function bases; cushion compacts | Global and Korean brands | Since 2000s | Company claims the world's first triple-function BB cream; Yuanta (Jan 2025) cites bulk cushion orders |
| Colour cosmetics | Lipsticks, mascara, other colour items | Brand owners | Ongoing | S&P description |
| Functional cosmetics | Whitening, anti-wrinkle, UV, acne-care functional claims (MFDS) | Brand owners | Ongoing | S&P description |
| Sheet and hydrogel masks | Hydrogel masks from the Cheongju plant (>1m sheets/month at start; medium-term revenue ambition reported by Meritz) | Indie brands, global | Cheongju plant opened Apr 2025 | Meritz (May 2025) |
| Scalp, body and bath care | Scalp care, body lotions and washes | Brand owners | Expanding | Ochang plant to add premium hair and body (company, Jun 2026) |
| Sun care | Sunscreens (MFDS functional) | Global indie brands | Expanding via Ochang | Company (Jun 2026) |
| ODM development services | Formulation development, proposals, stability and efficacy testing, regulatory dossiers | All customers | Ongoing | Pangyo Central Research Institute |
| Turnkey supply | Packaging procurement and assembly | Customers preferring a one-stop service | Ongoing | IR books split revenue into turnkey and non-turnkey |
Englewood Lab (US & Korea)
| Product line / capability | Description | Target customer | Status | Flagship / evidence |
|---|---|---|---|---|
| Skincare (US-made) | "Made in USA" skincare at the Totowa, NJ cGMP plant | US indie brands, prestige brands, K-beauty brands seeking US production | Core | 93%+ of 2024 revenue from US customers (Dealsite) |
| OTC sunscreens — "RTG OTC" | Ready-To-Go FDA OTC-compliant sunscreen bases that brands can launch quickly | K-beauty and US indie brands entering US sun care | Development completed 1Q25; selling from 2Q25 | Cosmorning (May 2025); OTC SKU expansion drove 3Q25 (Hanwha) |
| Other OTC drug-cosmetics | Acne and other monograph OTCs; in-house OTC Testing Lab | US brands | Ongoing | Englewood IR (OTC Testing Lab) |
| Colour cosmetics | Limited colour range | US brands | ~7% of revenue | Englewood disclosure |
| EWLK Incheon production | High-margin production for a key global client (EWLK OPM ~31–34% in 2025) | Global brand client "G" | Ongoing | Yuanta (Aug 2025, Feb 2026) |
| Certifications | cGMP, Health Canada, Australian TGA | Export customers | Held | Englewood IR books |
Revenue mix, 2Q26 (Englewood Lab disclosure via Butler.works): basic skincare 67%, functional/OTC 23%, colour 7%, services 3%, other 1%.
China (Cosmecca China)
| Product line | Description | Target | Status | Evidence |
|---|---|---|---|---|
| Colour cosmetics | Colour-led portfolio | Chinese local and global brands | Ongoing | Cosmorning (Aug 2025) headline on colour-led turnaround |
| Prestige skincare | New prestige skincare launches | Chinese brands | 4Q25 | KB (Feb 2026): China revenue +3.9% on prestige skincare |
| Sun-care and whitening functionals | Korea–China joint-lab products | China and Southeast Asia | In development 2025–26 | Kukinews (Nov 2025) |
| Halal-certified products | Halal certification for China and Southeast Asia | Southeast Asian markets | In progress | Cosmorning (Nov 2025) |
Packaging (SP BEAUTY GLOBAL Inc.)
A US packaging entity held through SP Beauty Global. Product and revenue details are not publicly disclosed. It is to be held directly by the parent after the December 2026 merger.
Financial Narrative
Source for all tables: S&P Global Market Intelligence via StockAnalysis.com (K-IFRS consolidated). Ratios were computed by the analyst as noted.
Per-share data and margins
Dividend notes:
-
FY2025 DPS of KRW 370 is per S&P.
-
FY2024 DPS of KRW 100 is implied by S&P's reported +270% dividend growth and by the 0.18% yield on brokers' June 2025 pages. Brokers showed a 0% yield before FY2024.
CAGR FY2021–FY2025: revenue 12.7%; operating income 42.8%; EPS 50.3%.
TTM to Jun 2026 (S&P): revenue KRW 772.05 bn; operating income KRW 99.63 bn (12.9%); EBITDA KRW 117.36 bn; net income to parent KRW 63.82 bn; EPS KRW 5,976.
1H 2026 (company, Dealsite): revenue KRW 411.2 bn (+46.8%); operating profit KRW 53.9 bn (+52.7%); net income KRW 39.9 bn (+99.5%).
Commentary — income statement:
FY2021–FY2022 trough: Revenue was flat at ~KRW 400 bn and operating margin fell to 2.6% in FY2022. Causes:
-
China losses (combined net losses of KRW 2.1 bn in 2021 and 5.1 bn in 2022; Dealsite),
-
under-utilised capacity built in 2018–19,
-
weak domestic road-shop clients.
FY2023 inflection: Gross margin jumped 650 bp to 22.6% as Korean indie-brand exports surged and Englewood Lab grew 36.5%. Operating leverage on a largely fixed cost base produced a 374% rise in operating profit.
FY2024 consolidation: The Korean parent carried the group (+22.3% revenue, +94% OP). Englewood Lab revenue fell 12% (customer turnkey switch and inventory adjustment) and China kept shrinking. Net income was flattered by a KRW 9.2 bn FX gain.
FY2025 acceleration: Revenue grew 22.2%, with Korea up ~34% and Englewood up 19%. Gross margin reached 24.6%. SG&A rose 33% (incentives, quality provisions, the Pangyo R&D centre). The effective tax rate normalised to 25.7%, which capped net-income growth at 6%.
1H 2026: Strongest period on record. Korean parent revenue was +91% in 1Q26 and +63% in 2Q26.
Balance sheet
At 30 June 2026 (S&P):
-
Total assets KRW 734.7 bn; cash and short-term investments KRW 91.0 bn.
-
Receivables KRW 209.8 bn; inventory KRW 109.0 bn.
-
Total debt KRW 233.0 bn, of which short-term borrowings KRW 159.7 bn and current long-term debt KRW 7.8 bn; net debt KRW 142.0 bn.
-
Common equity KRW 273.8 bn; minority interest KRW 60.8 bn.
-
BVPS KRW 25,639.
Additional paid-in capital fell from KRW 69.0 bn (FY2024) to KRW 47.1 bn (Jun 2026). This is consistent with the Englewood Lab tender premiums being booked as equity transactions with non-controlling interests (analyst interpretation).
Cash flow
TTM to Jun 2026 (S&P): OCF KRW 55.6 bn; capex KRW 49.6 bn; FCF KRW 6.0 bn; net borrowing KRW 57.4 bn; other financing −KRW 43.2 bn.
The −KRW 22.1 bn in FY2025 and −KRW 43.2 bn TTM match the 2025 (~KRW 21.9 bn) and 2026 (~KRW 43.1 bn) Englewood Lab tender offers.
Commentary — cash flow:
-
Cash conversion is weak relative to earnings. FY2025 OCF was 95% of net income incl. minorities, but FCF was negative because:
-
receivables rose by KRW 41.8 bn and inventory by KRW 14.4 bn,
-
capex reached KRW 61.4 bn (buildings jumped from KRW 79.5 bn to KRW 168.1 bn gross; Pangyo Central Research Institute and Cheongju plant).
-
-
In 1H 2026 receivables rose a further ~KRW 53 bn, and inventory rose ~KRW 30 bn on rapid growth.
-
The Englewood tender offers (~KRW 65 bn combined) and capex were funded by short-term borrowing. Short-term debt rose from KRW 78.3 bn at end-2024 to KRW 159.7 bn at June 2026.
-
The Ochang commitment (≈KRW 200 bn, of which KRW 64 bn is the land and buildings purchase) is roughly 3× FY2025 OCF. Further borrowing or other funding is likely; no equity issuance has been announced.
Ratios (analyst-computed from S&P data)
TTM June 2026 (S&P): ROE 24.8%; ROA 9.5%; ROIC 16.2%; current ratio 1.30; debt/equity 0.70; debt/EBITDA 1.99; interest coverage 18.3x; asset turnover 1.17; Altman Z 3.21; Piotroski F 5.
Commentary — ratios:
-
Returns have structurally reset, with ROIC rising from low single digits to mid-teens.
-
DSO has drifted up from 69 to 88 days. This reflects longer terms granted to indie-brand clients during rapid growth and is a credit-risk monitorable.
-
Leverage is moderate on EBITDA (net debt/EBITDA 0.9x at FY2025; ~1.2x TTM June 2026). However, the debt is heavily short-dated (~72% due within a year at June 2026), which creates refinancing exposure while the Ochang build is under way.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment revenue (KRW Bn)
| Segment revenue (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Korea (parent) | 268.8 | 328.7 | 441.5 |
Englewood Lab (US+Korea, consolidated) | 206.8 | 182.2 | 216.8 |
China (Cosmecca China) | 50.6 | 40.4 | 34.0 |
Intersegment eliminations | -55.5 | -27.0 | -51.4 |
Consolidated revenue | 470.7 | 524.3 | 640.9 |
Segment operating profit (KRW Bn)
| Segment operating profit (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Korea (parent) | 22.9 | 44.5 | 47.7 |
Englewood Lab (consolidated) | 28.9 | 18.8 | 37.4 |
China | — | -1.1 | -1.9 |
Consolidated operating profit | 49.2 | 60.4 | 83.5 |
Revenue by Segment (%) and Segment Margins & Growth (%)
| Segment metric (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Korea OPM | 8.5 | 13.5 | 10.8 |
Englewood Lab OPM | 14.0 | 10.3 | 17.3 |
China OPM | — | -2.7 | -5.6 |
Korea revenue YoY growth | — | 22.3 | 34.3 |
Englewood Lab revenue YoY growth | 36.5 | -11.9 | 19.0 |
China revenue YoY growth | — | -20.1 | -15.8 |
Korea share of gross segment revenue | 51.1 | 59.6 | 63.8 |
Englewood Lab share of gross segment revenue | 39.3 | 33.0 | 31.3 |
China share of gross segment revenue | 9.6 | 7.3 | 4.9 |
Quarterly Metric Details
| Quarterly metric (KRW Bn) | 1Q25 | 2Q25 | 3Q25 | 4Q25 | 1Q26 | 2Q26 |
|---|---|---|---|---|---|---|
Consolidated revenue | 118.4 | 161.7 | 182.4 | 178.1 | 185.1 | 226.1 |
Consolidated operating profit | 12.3 | 23.0 | 27.2 | 20.9 | 21.9 | 32.1 |
Korea revenue | 74.3 | 110.0 | 129.8 | 127.3 | 142.2 | 178.8 |
Korea operating profit | 8.0 | 13.8 | 14.5 | 11.3 | 17.8 | 24.5 |
Englewood Lab revenue | 42.5 | 57.5 | 61.8 | 54.5 | 49.7 | 51.9 |
Englewood Lab operating profit | 4.6 | 10.1 | 13.2 | 9.3 | 5.6 | 8.7 |
China revenue | 8.8 | 8.6 | 8.1 | 8.5 | — | 7.7 |
China operating profit | -0.6 | -1.1 | -0.6 | 0.4 | — | -1.2 |
Income Statement and Margin Analysis (%)
| Metric (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue | 396.5 | 399.4 | 470.7 | 524.3 | 640.9 |
Revenue growth (%) | 16.9 | 0.7 | 17.9 | 11.4 | 22.2 |
Cost of revenue | 324.6 | 335.0 | 364.2 | 400.2 | 483.5 |
Gross profit | 71.9 | 64.4 | 106.6 | 124.1 | 157.4 |
SG&A | 31.4 | 33.7 | 36.3 | 40.1 | 53.2 |
R&D expense | 11.8 | 13.6 | 13.3 | 13.8 | 16.9 |
Operating income (EBIT) | 20.1 | 10.4 | 49.2 | 60.4 | 83.5 |
D&A | 16.4 | 16.7 | 16.8 | 17.8 | 16.5 |
EBITDA | 36.5 | 27.1 | 65.9 | 78.2 | 100.0 |
Interest expense | 3.0 | 3.7 | 4.0 | 3.2 | 3.5 |
FX gain (loss) | 2.9 | -0.1 | 0.0 | 9.2 | -0.3 |
Pre-tax income | 17.5 | 6.4 | 46.1 | 67.6 | 77.9 |
Income tax | 0.5 | 0.4 | 12.2 | 13.9 | 20.0 |
Net income incl. minorities | 17.0 | 6.0 | 33.9 | 53.7 | 57.8 |
Minority interest | 8.1 | 3.3 | 11.6 | 10.9 | 12.4 |
Net income to parent | 8.9 | 2.7 | 22.3 | 42.8 | 45.4 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansPer-Share Data and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
EPS basic (KRW) | 834 | 249 | 2,090 | 4,008 | 4,255 |
EPS diluted (KRW) | 834 | 249 | 2,090 | 4,008 | 4,255 |
Dividend per share (KRW) | 0 | 0 | 0 | 100 | 370 |
Gross margin (%) | 18.1 | 16.1 | 22.6 | 23.7 | 24.6 |
Operating margin (%) | 5.1 | 2.6 | 10.4 | 11.5 | 13.0 |
EBITDA margin (%) | 9.2 | 6.8 | 14.0 | 14.9 | 15.6 |
Net margin to parent (%) | 2.2 | 0.7 | 4.7 | 8.2 | 7.1 |
Effective tax rate (%) | 3.1 | 5.8 | 26.5 | 20.6 | 25.7 |
Balance Sheet and Per-Share Data
| Metric (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets | 391.6 | 392.8 | 432.6 | 518.0 | 631.8 |
Cash and short-term investments | 30.1 | 26.4 | 39.4 | 64.4 | 81.6 |
Accounts receivable | 75.3 | 80.3 | 108.8 | 114.5 | 155.3 |
Inventory | 67.0 | 71.2 | 65.6 | 67.0 | 78.8 |
Property, plant and equipment | 155.0 | 155.0 | 159.1 | 207.2 | 248.2 |
Goodwill and intangibles | 42.4 | 40.2 | 37.8 | 36.3 | 35.6 |
Accounts payable | 30.4 | 34.2 | 44.1 | 38.7 | 60.7 |
Short-term debt incl. current LTD and leases | 77.1 | 83.6 | 79.8 | 90.7 | 137.9 |
Long-term debt incl. leases | 50.8 | 37.4 | 28.9 | 31.7 | 34.0 |
Total debt | 127.9 | 121.0 | 108.7 | 122.4 | 172.0 |
Net debt | 97.8 | 94.6 | 69.3 | 58.0 | 90.3 |
Common equity (parent) | 142.3 | 146.7 | 169.5 | 218.4 | 252.7 |
Minority interest | 54.1 | 60.4 | 72.6 | 89.2 | 83.5 |
Total equity | 196.3 | 207.0 | 242.2 | 307.6 | 336.2 |
Working capital | 47.9 | 43.8 | 66.6 | 84.9 | 82.3 |
Book value per share (KRW) | 13,319 | 13,732 | 15,874 | 20,450 | 23,663 |
Cash Flow
| Metric (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow | 7.9 | 16.7 | 42.0 | 69.5 | 55.0 |
Change in working capital | -22.4 | -11.3 | -22.2 | -2.7 | -28.8 |
Capital expenditure | 9.0 | 11.6 | 18.6 | 48.7 | 61.4 |
Free cash flow | -1.1 | 5.1 | 23.4 | 20.8 | -6.3 |
Dividends paid (consolidated, incl. to NCI) | 0.0 | 0.0 | 0.0 | 1.3 | 2.3 |
Share buybacks | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net debt issued (repaid) | -1.8 | -10.3 | -13.2 | 3.2 | 48.2 |
Other financing (NCI share purchases) | 0.0 | 0.0 | 0.0 | 0.0 | -22.1 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE to parent, year-end equity (%) | 6.3 | 1.8 | 13.2 | 19.6 | 18.0 |
ROA, NI incl. NCI / year-end assets (%) | 4.3 | 1.5 | 7.8 | 10.4 | 9.1 |
ROIC, NOPAT at 22% tax / (equity + net debt) (%) | 5.3 | 2.7 | 12.3 | 12.9 | 15.3 |
Current ratio (x) | 1.35 | 1.31 | 1.43 | 1.50 | 1.33 |
Debt / equity (x) | 0.65 | 0.58 | 0.45 | 0.40 | 0.51 |
Net debt / EBITDA (x) | 2.68 | 3.49 | 1.05 | 0.74 | 0.90 |
Interest coverage, EBIT / interest (x) | 6.8 | 2.8 | 12.2 | 18.9 | 23.6 |
Asset turnover, revenue / year-end assets (x) | 1.01 | 1.02 | 1.09 | 1.01 | 1.01 |
Days sales outstanding | 69.3 | 73.4 | 84.4 | 79.7 | 88.4 |
Days inventory outstanding | 75.3 | 77.6 | 65.7 | 61.1 | 59.5 |
Days payables outstanding | 34.2 | 37.3 | 44.2 | 35.3 | 45.8 |
Cash conversion cycle (days) | 110.4 | 113.7 | 105.9 | 105.5 | 102.1 |
Revenue by Region
| Region by producing entity (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Korea (parent) | 268.8 | 328.7 | 441.5 |
United States (Englewood Lab, incl. EWLK Incheon) | 206.8 | 182.2 | 216.8 |
China | 50.6 | 40.4 | 34.0 |
Regional growth (YoY %)
| Regional growth (YoY %) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Korea (parent) | — | 22.3 | 34.3 |
United States (Englewood Lab) | 36.5 | -11.9 | 19.0 |
China | — | -20.1 | -15.8 |
Capital Markets
| Item | Value | Source |
|---|---|---|
Latest close | KRW 111,800 (12 Oct 2026) | Money Today |
52-week high / low | KRW 155,500 / 61,200 | WiseReport |
1-month return | −21.1% (to 2 Oct 2026) | WiseReport |
3-month return | +30.5% (to 2 Oct 2026) | WiseReport |
6-month return | +41.4% (to 2 Oct 2026) | WiseReport |
1-year return | +52.4% (to 2 Oct 2026) | WiseReport |
3-year return | ≈+311% (KRW 27,200 on 15 Sep 2023 to KRW 111,800) | Hanwha (Sep 2023); analyst calculation |
5-year return | The stock troughed near KRW 6,500 in 2022–23 (52-week low cited Sep 2023) | Hanwha |
Beta (5Y) | 1.07 | S&P |
Valuation Multiples
| Multiple | Cosmecca Korea |
|---|---|
Market cap (KRW Bn) | 1,194 |
Enterprise value incl. NCI (KRW Bn) | 1,397 |
P/E TTM (x) | 18.7 |
P/E on Hana FY2026E (x) | 15.5 |
EV/EBITDA TTM (x) | 11.9 |
EV/Sales TTM (x) | 1.81 |
P/B (x) | 4.36 |
Dividend yield (%) | 0.33 |
Analyst Ratings & Targets
| Broker | Date | Rating | Target price (KRW) |
|---|---|---|---|
KB Securities | 13 Oct 2026 | Buy | 140,000 |
Kyobo Securities | 11 Aug 2026 | Buy | 150,000 |
NH Investment & Securities | Aug 2026 | Buy | 140,000 |
Hanwha Investment & Securities | Aug 2026 | Buy | 130,000 |
Samsung Securities | 8 Jul 2026 | Buy | 110,000 |
Yuanta Securities | Jul 2026 | Buy | 120,000 |
S&P consensus (11 analysts) | Sep 2026 | Strong Buy | 127,727 average |
Dividend history
| Dividend history | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
DPS (KRW) | 0 | 0 | 0 | 100 | 370 |
Payout to parent NI (%) | 0 | 0 | 0 | 2.5 | 8.7 |
Debt bucket (KRW Bn)
| Debt bucket (KRW Bn) | Jun 2026 |
|---|---|
Short-term borrowings | 159.7 |
Current portion of long-term debt | 7.8 |
Current leases | 2.6 |
Long-term debt | 58.4 |
Long-term leases | 4.6 |
Total debt | 233.0 |
Analyst Conclusions
Guidance and consensus
| Forecast (KRW Bn) | FY2025A | FY2026E | FY2027E |
|---|---|---|---|
| Revenue (Hana) | 640.9 | 832.5 | 1,024.3 |
| Operating profit (Hana) | 83.5 | 112.6 | 145.3 |
| Revenue (Hanwha, May 2026) | 640.9 | 788.0 | 869.0 |
| Operating profit (Hanwha, May 2026) | 83.5 | 106.0 | 122.0 |
Management guidance: FY2026 revenue +30% YoY (≈KRW 833 bn), raised twice in 2026 from +15%. The revised margin guidance is not captured; the prior guide was 13.5%.
Broker forecasts: - KB quarterly path: 3Q26E revenue KRW 219.9 bn / OP KRW 31.0 bn; 4Q26E revenue KRW 220.5 bn / OP KRW 30.4 bn. This implies FY2026E revenue of ≈KRW 851.6 bn and OP of ≈KRW 115.4 bn.
S&P three-year forecasts: revenue +19.0% and EPS +28.9%.
Bull case
-
Structural share gain in K-beauty ODM. Korean parent revenue grew 91% and 63% in 1Q and 2Q26, well above Korea's +27% export growth. Broadening clients (5th–10th clients now 2–3% each) suggest growth is not single-client driven.
-
Operating leverage plus ownership step-up. OPM has expanded from 2.6% to ~13% in three years. Raising the Englewood stake to 66.7% adds attributable earnings; Hanwha's FY2026E controlling NI is KRW 73 bn (+61%).
-
Capacity unlock and category expansion. Ochang from 2027 targets masks, sun care, and hair and body, making Hana's FY2027 KRW 1 trn revenue achievable at stable margins.
Bear case
-
Cash conversion and leverage. FCF was negative in FY2025, and receivables plus inventory rose ~KRW 83 bn in 1H26. Short-term debt doubled to KRW 160 bn before the ~KRW 200 bn Ochang spend. A demand pause would expose the balance sheet.
-
Cyclical, fad-driven demand. Indie hits have short lives. 3Q26 is already expected to miss on supply bottlenecks, and US destocking is recurring. The 21% 1-month share-price drop shows sentiment sensitivity.
-
Governance overhang. Two family executives were indicted, the 2025 KOSPI transfer was rejected, and there is a 39% family bloc. These factors could cap the multiple and delay a KOSPI move.
Catalysts and monitorables (next 12 months)
-
3Q26 results (~10 Nov 2026): size of the miss, and evidence of 4Q order recovery.
-
FY2026 results (~Feb 2027) and FY2027 guidance.
-
Ochang financing structure and the 2027 start-up timetable.
-
Progress of the sons' trial.
-
Englewood EWLK client order trends; RTG OTC traction.
-
China reaching breakeven.
-
Receivable days and short-term debt.
-
Any renewed KOSPI transfer filing.
-
Confirmation of the quarterly dividend policy.
-
KRW/USD.
Analyst verdict
Cosmecca Korea has moved from a sub-scale, low-margin contract manufacturer to the fastest-growing and most profitable of Korea's three listed cosmetics ODMs.
Earnings trajectory: Operating profit rose eightfold from the FY2022 trough of KRW 10.4 bn to KRW 83.5 bn in FY2025. TTM operating profit is near KRW 100 bn, and management raised FY2026 revenue guidance twice to +30%.
Quality of growth: It is driven by a broadening base of Korean indie and derma clients rather than one hero brand. Englewood Lab gives Cosmecca a rare US manufacturing platform as tariffs push brands toward local production.
Strategic progress: Raising its Englewood stake to two-thirds and committing ~KRW 200 bn to Ochang give credibility to the KRW 1 trillion revenue ambition. Hana's FY2027 forecast already reaches it.
The balance sheet and governance have not kept pace with the income statement:
Funding: Free cash flow is near zero because receivables, inventory, capex, and two tender offers have been funded with short-term bank debt, now KRW 160 bn.
Execution risk: The Ochang build roughly triples annual capex needs just as 3Q26 shows supply-chain strain and US client destocking.
Governance: The August 2026 indictment of the founder's two sons and the failed 2025 KOSPI transfer are reminders that governance remains a discount factor, despite the March 2026 board reforms.
At ~KRW 112,000 the shares trade on roughly 15–16x FY2026E earnings and ~12x TTM EV/EBITDA. That is a premium to the company's own history but modest relative to its growth and returns (TTM ROIC ~16%, ROE ~25%). The sell-side is uniformly positive, with targets of KRW 110,000–150,000.
Net assessment: fundamentally attractive and structurally advantaged, with growth quality validated by customer diversification. Execution on Ochang, working-capital discipline, and resolution of the governance overhang are the variables that will decide whether the market rewards Cosmecca with a peer-level or premium multiple. Investors should treat the 3Q26 print, the 4Q26 order recovery, and the Ochang funding plan as the key near-term tests.
APPENDIX — SOURCE REGISTER
-
S&P Global Market Intelligence via StockAnalysis.com — income statement, balance sheet, cash flow, statistics (KOSDAQ:241710), accessed 2026: https://stockanalysis.com/quote/kosdaq/241710/financials/income-statement/ ; https://stockanalysis.com/quote/kosdaq/241710/financials/balance-sheet/ ; https://stockanalysis.com/quote/kosdaq/241710/financials/cash-flow-statement/ ; https://stockanalysis.com/quote/kosdaq/241710/statistics/
-
Cosmecca Korea IR Books 1Q25, 2Q25, 3Q25, 4Q24 (via alphasquare / pstatic): https://file.alphasquare.co.kr/media/pdfs/company-ir/20251110%EC%BD%94%EC%8A%A4%EB%A9%94%EC%B9%B4%EC%BD%94%EB%A6%AC%EC%95%84_2025%EB%85%84_3%EB%B6%84%EA%B8%B0_%EC%A3%BC%EC%9A%94_%EA%B2%BD%EC%98%81_%ED%98%84%ED%99%A9.pdf
-
Kukinews, 3Q25 results (Nov 2025): https://www.kukinews.com/article/view/kuk202511060201
-
Cosmorning, 1Q25 / 2Q25 / tender offers / Ochang (2025–2026): https://www.cosmorning.com/news/article.html?no=50456 ; https://www.cosmorning.com/news/article.html?no=51042 ; https://www.cosmorning.com/news/article.html?no=52277 ; https://www.cosmorning.com/news/article.html?no=52956
-
CosinKorea, 2Q26 results (Aug 2026): https://www.cosinkorea.com/news/article.html?no=58057
-
Hana Securities, 2Q26 review (Aug 2026): https://stock.pstatic.net/stock-research/company/57/20260811_company_167638000.pdf
-
Hanwha Investment & Securities, 1Q26 review (May 2026): https://stock.pstatic.net/stock-research/company/16/20260511_company_426942000.pdf
-
Yuanta Securities, 2Q25 review (Aug 2025): https://stock.pstatic.net/stock-research/company/18/20250812_company_927146000.pdf
-
Meritz Securities, 1Q25 comment (May 2025): https://file.alphasquare.co.kr/media/pdfs/company-report/%EB%A9%94%EB%A6%AC%EC%B8%A020250513%EC%BD%94%EC%8A%A4%EB%A9%94%EC%B9%B4%EC%BD%94%EB%A6%AC%EC%95%84.pdf
-
Asia Economy, insider-trading indictment (Sep 2026): https://view.asiae.co.kr/article/2026083110385053473
-
Asia Economy, Yuanta TP raise / 4Q25 (Feb 2026): https://view.asiae.co.kr/article/2026022308105137428
-
Asia Economy, Samsung TP raise (Jul 2026): https://view.asiae.co.kr/en/article/2026070815573831837
-
Asia Economy, Hansol Technics Ochang sale (Jun 2026): https://view.asiae.co.kr/article/2026060514395141830
-
Dealsite, Ochang investment and SP Beauty Global merger (Sep 2026): https://dealsite.co.kr/articles/169452
-
Dealsite, governance overhaul and KOSPI transfer (Jul 2026): https://dealsite.co.kr/articles/165007
-
Dealsite, KRW 1 trn goal (Jul 2026): https://dealsite.co.kr/articles/164905
-
Dealsite, 2026 tender offer (Mar 2026): https://dealsite.co.kr/articles/157720
-
Dealsite, Englewood Lab diversification (Aug 2025): https://dealsite.co.kr/articles/145738
-
Dealsite, China and Cho Hyun-seok (Jul 2025): https://dealsite.co.kr/articles/145509
-
SmartToday, 2025 tender offer (Feb 2025): https://www.smarttoday.co.kr/ko-kr/articles/71789
-
SmartToday, Kyobo TP KRW 150k (Aug 2026): https://www.smarttoday.co.kr/ko-kr/articles/110308
-
Money Today, KB TP KRW 140k (13 Oct 2026): https://www.mt.co.kr/stock/2026/10/13/2026101308392487762
-
Sidae, KB on 4Q25 (Feb 2026): https://www.sidae.com/article/2026022308175774586
-
Digital Daily, Ochang plant (Jun 2026): https://www.ddaily.co.kr/page/view/2026060517080678126
-
WiseReport company monitor (Oct 2026): https://comp.wisereport.co.kr/company/c1010001.aspx?cmp_cd=241710
-
Daum/News, FY2024 subsidiary performance (Apr 2025): https://v.daum.net/v/20250424000105570
-
Butler.works, Englewood Lab financials: https://www.butler.works/ko/companies/01165739
-
Hankyung Magazine, Cosmax FY2025 (Feb 2026): https://magazine.hankyung.com/business/article/202602238841b
-
Kukinews, Kolmar / Cosmax FY2025 (Feb 2026): https://www.kukinews.com/article/view/kuk202602250265
-
Cosmorning, 2016 IPO: https://www.cosmorning.com/news/article.html?no=3886
-
Hankyung, FY2016 results (Feb 2017): https://www.hankyung.com/amp/201702201534i
-
CNC News, FY2018 results (Feb 2019): https://www.cncnews.co.kr/news/article.html?no=4599
-
E-today, Pinghu plant (Aug 2019): https://www.etoday.co.kr/news/view/1793466
-
Fnnews, ODM capex race (Sep 2026): https://www.fnnews.com/news/202609110601496254
-
The Fact, China restructuring and governance: https://news.tf.co.kr/read/ogmeta/2286537.htm
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / role notes | Prior roles / education / age |
|---|---|---|---|
Cho Im-rae (조임래) | Chairman and Co-CEO; founder | Founded the company in 1999; CEO since founding | — |
Park Eun-hee (박은희) | Co-CEO | Named co-CEO in 2025–2026 press and IR. Listed as lead holder of the largest shareholder group (39.0% with related parties) | — |
Cho Hyun-seok (조현석) | President (사장), Cosmecca Korea | Heads the Global Sales Division and Management Support Division. Took global sales leadership in 2025 with a mandate to fix China. Holds ~3% | Founder's eldest son. Indicted Aug 2026 |
Cho Hyun-chul (조현철) | CEO, Englewood Lab | Leads US operations. Holds ~3% of Cosmecca | Founder's second son. Indicted Aug 2026 |
Kim Hyung-yeol (김형열) | General Manager, Cosmecca China | Hired Mar 2025 | Formerly at Chinese cosmetics brand Proya |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Notes |
|---|---|---|
Choi Su-gyu (최수규) | Outside director; Board Chair; audit committee member | Chair separated from CEO by articles amendment, Mar 2026 |
Koo Bon-kwang (구본광) | Outside director; Audit Committee Chair | Former member of the KRX KOSPI listing and disclosure committee |
Kim Ju-deok (김주덕) | Outside director; audit committee member | — |
Two inside directors | Executive directors | Names not confirmed in sources reviewed; likely include the co-CEOs |
Major Shareholders
| Holder | Stake (%) | Date / source |
|---|---|---|
Park Eun-hee and related parties (4) | 39.0 | Hanwha, May 2026 |
National Pension Service (and 1 related) | 12.5 | Hanwha, May 2026 (up from 6.2% in Sep 2023) |
KB Asset Management (and 1 related) | 6.1 | Hanwha, May 2026 |
Cho Hyun-seok | ~3 (included in insider group) | Asia Economy, Sep 2026 |
Cho Hyun-chul | ~3 (included in insider group) | Asia Economy, Sep 2026 |
Foreign investors (aggregate) | 18.7 | Hanwha, May 2026 (8.95% in Jan 2025) |
Insiders (S&P definition) | 45.0 | StockAnalysis, Sep 2026 |
Institutions (S&P definition) | 31.2 | StockAnalysis, Sep 2026 |
Free float | ~5.87m shares (55%) | StockAnalysis |
Competitive Landscape
Key Competitors
| Competitor | Listing | Segment overlap | Revenue (latest) | Positioning vs Cosmecca |
|---|---|---|---|---|
Cosmax | KOSPI 192820 | Korea, US, China skincare, colour, sun care ODM | FY2025 KRW 2,398.8 bn (+10.7%); OP KRW 195.8 bn | Self-described global #1 cosmetics ODM; ~3.7× Cosmecca's revenue; Korea unit KRW 1,526.4 bn |
Kolmar Korea | KOSPI 161890 | Korea and US skincare and sun care ODM; also pharma (HK inno.N) | FY2025 KRW 2,722.4 bn; OP KRW 239.6 bn (consolidated, incl. pharma) | Sun care leader; non-cosmetics ~half of revenue; US plants |
C&C International | KOSDAQ 352480 | Colour cosmetics (lip, base) ODM | — | Colour specialist; China presence |
Hankook Cosmetics Manufacturing | KOSPI 003350 | Korean contract manufacturing | — | Smaller domestic OEM |
Intercos | Euronext Milan (ICOS) | Global colour, skincare ODM (Europe, US, Asia) | — | Global colour leader |
KDC/One | Private | North American contract manufacturing | — | US competitor to Englewood Lab |
Nihon Kolmar | Private (Japan) | Japanese ODM | — | Japan market |
Toyo Beauty | Japan | Japanese ODM | — | Japan market |
Cosmax USA / Cosmax West | Subsidiary | US ODM | Cosmax US revenue FY2025 KRW 132.6 bn | Direct US rival to Englewood |
Kolmar USA | Subsidiary | US ODM (sun care) | 2024 KRW 57.9 bn (+55%) | Direct US rival |
In-house manufacturing at large brand houses (Amorepacific, LG H&H) | KOSPI | Captive production | Amorepacific FY2025 KRW 4.25 trn | Substitute rather than direct competitor |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | Cosmecca Korea | Cosmax | Kolmar Korea |
|---|---|---|---|
Revenue (KRW Bn) | 640.9 | 2,398.8 | 2,722.4 |
Revenue growth (%) | 22.2 | 10.7 | — |
Operating profit (KRW Bn) | 83.5 | 195.8 | 239.6 |
Operating margin (%) | 13.0 | 8.2 | 8.8 |
R&D intensity (%) | 2.6 | — | — |



